The UK Government’s decision to confirm the indefinite recognition of CE-marked medical devices represents a significant development for the medical technology industry, providing manufacturers with greater regulatory certainty while helping to safeguard patient access to essential healthcare technologies across Great Britain.
Announced by the Medicines and Healthcare products Regulatory Agency (MHRA) on 21st October 2026, the decision confirms that medical devices and in vitro diagnostic devices (IVDs) that meet applicable EU requirements and carry the appropriate CE marking can continue to access the Great Britain market without requiring an additional UK-specific approval solely as a consequence of the existing recognition arrangements.
For manufacturers, healthcare providers and investors, this announcement has implications extending well beyond regulatory compliance. It influences market access strategies, supply chain resilience, investment decisions and the UK’s attractiveness as a destination for medical technology innovation.
Regulatory certainty: A significant consideration for manufacturers
The decision follows a government consultation conducted between 16 February and 10 April 2026, which attracted more than 1,000 responses from patients, healthcare organisations, industry representatives and other stakeholders.
The consultation highlighted the importance of maintaining a proportionate regulatory framework that supports patient safety without introducing unnecessary administrative burdens or barriers to market access.
The scale of CE marking’s role in the UK market is particularly noteworthy. According to the MHRA, more than 90% of medical devices registered for use in Great Britain currently carry a CE mark. Continued recognition therefore helps preserve established routes to market for a substantial proportion of the medical technology products used by the NHS and private healthcare providers.
Without this long-term recognition, manufacturers relying on CE marking could have faced additional regulatory requirements, associated costs and potential delays in maintaining access to the British market.
For businesses operating across multiple European markets, the confirmed approach offers a more predictable basis for regulatory planning, portfolio management and resource allocation. It also reduces the prospect of duplicative approval processes where an appropriate EU conformity assessment has already been completed.
However, indefinite recognition should not be interpreted as the removal of UK regulatory obligations. Manufacturers must continue to comply with the applicable requirements governing the devices they place on the Great Britain market, including relevant registration, safety, vigilance and post-market surveillance obligations.
Protecting patient access and strengthening supply resilience
Regulatory decisions have direct consequences for healthcare delivery. Medical devices and IVDs underpin a wide range of clinical activities, from diabetes management and orthopaedic procedures to laboratory diagnostics, surgical interventions and patient monitoring.
Maintaining established routes to market helps reduce the risk that additional regulatory requirements could contribute to product discontinuation, delayed launches or avoidable supply pressures.
For the NHS, the decision provides greater continuity in the availability of technologies already integrated into clinical pathways. For manufacturers and distributors, it supports more stable market planning and reduces uncertainty about the regulatory status of CE-marked products in Great Britain.
These considerations are particularly important in a market where device portfolios can include thousands of products, each with its own conformity assessment, documentation, labelling and lifecycle management requirements.
Nevertheless, regulatory recognition alone cannot guarantee uninterrupted supply. Product availability will continue to depend on manufacturing capacity, procurement arrangements, commercial decisions, logistics and the ability of suppliers to meet applicable regulatory requirements.
The announcement should therefore be viewed as an important component of supply resilience rather than a standalone solution to every potential supply chain challenge.
CE marking and UKCA: Understanding the regulatory landscape
The UK’s approach continues to accommodate both CE marking and the domestic UK Conformity Assessed (UKCA) marking route.
The UKCA route remains available for medical devices placed on the Great Britain market. The Government is also progressing reforms intended to modernise the domestic regulatory framework through a pre-market statutory instrument that will update the requirements applicable to UKCA-marked devices.
For manufacturers, the practical implication is that regulatory strategy should remain product-specific. Businesses need to understand which conformity assessment arrangements apply to their products, how those arrangements interact with Great Britain market access requirements, and what documentation and ongoing compliance activities are necessary.
Companies should avoid treating indefinite CE recognition as a reason to defer broader regulatory planning. Although the decision provides long-term certainty regarding recognition, the surrounding regulatory framework continues to evolve.
Organisations with established CE-marked portfolios should review their regulatory roadmaps, monitor the implementation of future reforms and ensure that internal processes remain aligned with applicable UK requirements.
For businesses considering a UKCA route, the decision also creates an opportunity to reassess the commercial rationale, resource requirements and strategic benefits of maintaining or pursuing a separate domestic conformity assessment pathway.
Patient safety remains central to the framework
The Government’s decision to continue recognising CE marking sits alongside strengthened post-market surveillance and reporting requirements.
The MHRA will retain responsibility for overseeing medical devices placed on the UK market, including monitoring safety signals through mechanisms such as the Yellow Card scheme and working with international regulatory partners to exchange information on emerging risks.
This distinction is important. Recognition of an overseas conformity assessment framework does not remove the need for effective national oversight, ongoing vigilance or timely regulatory intervention where safety concerns arise.
For manufacturers, post-market compliance remains a core operational responsibility. Companies should ensure that adverse incident reporting, complaint handling, trend monitoring, corrective action processes and communication with relevant regulatory authorities are appropriately resourced.
A robust regulatory strategy must therefore balance efficient market access with the ability to identify, assess and respond to emerging safety issues throughout a device’s lifecycle.
From a commercial perspective, effective vigilance is also fundamental to protecting product reputation, maintaining stakeholder confidence and supporting sustainable market access.
Preparing for the next phase of UK medical device regulation
Alongside the continuation of CE recognition, the Government has signalled its intention to develop a more modern and adaptable medical device regulatory framework.
This includes seeking enabling powers through primary legislation to support a future licensing approach, with the stated objective of responding more effectively to advances in medical technology, including software and artificial intelligence-enabled medical devices.
These proposals reflect the growing complexity of the MedTech landscape. Digital health products, software as a medical device and AI-enabled technologies can present regulatory considerations that differ from those associated with more traditional hardware-based products.
The challenge for regulators is to create a framework that supports innovation while maintaining appropriate standards of safety, performance and clinical assurance.
For industry, the direction of travel reinforces the importance of maintaining regulatory intelligence capabilities and anticipating changes rather than responding only when new requirements become mandatory.
Manufacturers developing digital or AI-enabled technologies should pay particular attention to emerging UK requirements, the implications for product classification and conformity assessment, and the potential impact of future licensing arrangements on development and commercialisation strategies.
Implications for the UK’s Life Sciences ambitions
The decision also aligns with the broader objectives of the Government’s Life Sciences Sector Plan and 10 Year Health Plan, both of which seek to support the development and adoption of health technologies.
A predictable regulatory environment can contribute to the UK’s attractiveness as a market for medical technology companies by reducing uncertainty, supporting investment planning and facilitating access to established international regulatory pathways.
It also reflects the ambitions of the MHRA’s 2030 Strategy, which includes expanding reliance and recognition arrangements with trusted regulators, reducing unnecessary regulatory burdens and supporting timely access to medical innovation.
Steve Lee, Executive Director of Regulation at the Association of British HealthTech Industries (ABHI), welcomed the decision, highlighting the importance of regulatory predictability and avoiding unnecessary duplication in industry investment decisions.
From an industry perspective, the commercial benefits are clear in principle: a more predictable route to market can help companies allocate resources more efficiently, maintain product portfolios and evaluate the UK within their wider international launch strategies.
However, the long-term impact will depend on implementation, the clarity of accompanying guidance and the continued effectiveness of the UK’s wider regulatory and healthcare systems.
Regulatory certainty is an important factor in attracting investment, but it operates alongside other considerations, including reimbursement, procurement, clinical adoption, market size and the availability of skilled regulatory and technical personnel.
What should medical device manufacturers do now?
Although the announcement provides long-term clarity on CE recognition, manufacturers should use this opportunity to review their regulatory and commercial strategies.
Five priorities warrant particular attention:
1. Review market access strategies. Confirm which products rely on CE marking for access to Great Britain and ensure that the applicable recognition arrangements and product-specific requirements are understood.
2. Reassess regulatory investment. Review planned UKCA activities in light of the confirmed position, considering product portfolios, commercial objectives, conformity assessment costs and the intended use of each regulatory route.
3. Maintain post-market surveillance readiness. Ensure vigilance, incident reporting, complaint management and corrective action procedures meet applicable UK requirements and can respond effectively to emerging safety concerns.
4. Monitor forthcoming regulatory reforms. Track the development of the pre-market statutory instrument and any future legislative proposals concerning licensing, digital health and AI-enabled medical devices.
5. Strengthen regulatory governance. Ensure that regulatory affairs, quality, supply chain, commercial and senior leadership teams share a consistent understanding of the implications for product availability, compliance and investment planning.
These actions can help organisations translate the Government’s announcement into practical operational and strategic benefits.
Conclusion: Certainty today, continued reform tomorrow
The indefinite recognition of CE-marked medical devices is an important development for the Great Britain medical technology market. It preserves an established route to market for a substantial proportion of medical devices, reduces the prospect of duplicative approval requirements and provides greater certainty for manufacturers planning their UK operations.
For patients and healthcare providers, the decision supports continuity of access to the technologies on which modern healthcare depends. For industry, it provides a more predictable environment for regulatory planning, investment and product portfolio management.
However, this is not the end of UK medical device regulatory reform. The continued development of UKCA requirements, the potential introduction of future licensing arrangements and the evolving regulation of digital and AI-enabled technologies will require ongoing attention from manufacturers.
The strategic priority for industry should therefore be to take advantage of the certainty now provided while remaining prepared for the next phase of regulatory change. Ultimately, the success of this approach will depend on maintaining the right balance between patient safety, proportionate regulation, supply resilience and timely access to innovation. Achieving that balance will be essential if the UK is to strengthen its position as a competitive life sciences market while ensuring that patients and the NHS continue to benefit from safe, effective and innovative medical technologies.